Skip to main content

Roivant Sciences Ltd.

corporate_fare Company Profile

Roivant Sciences Ltd.

ROIV·NASDAQ·Life Sciences·CIK 0001635088

Roivant Sciences Ltd. is a biopharmaceutical company focused on developing and commercializing medicines. The company's pipeline includes several product candidates. Brepocitinib, a small molecule inhibitor of JAK1 and TYK2, is currently under review at the FDA for dermatomyositis with a PDUFA Date of 3Q 2026. It is also in Phase 3 development for non-infectious uveitis and cutaneous sarcoidosis, and in Phase 2b/3 development for lichen planopilaris, all under the subsidiary Priovant. IMVT-1402, a fully human monoclonal antibody targeting FcRn, is in development across several IgG-mediated autoimmune indications under the subsidiary Immunovant. These include Phase 2/3 trials for Difficult-to-Treat Rheumatoid Arthritis, Graves' Disease, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyneuropathy, and Sjögren's Disease, as well as a Phase 2 trial for Cutaneous Lupus Erythematosus. Mosliciguat, an inhaled sGC activator, is in Phase 2 development for pulmonary hypertension associated with interstitial lung disease under the subsidiary Pulmovant. Roivant advances its pipeline by creating subsidiaries, referred to as "Vants," to develop and commercialize its medicines and technologies. Beyond therapeutics, Roivant also incubates discovery-stage companies and health technology startups that complement its biopharmaceutical business.

Roivant Sciences Ltd. (NASDAQ:ROIV) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for ROIV at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Roivant Reports $770M Moderna Settlement Gain, Key Pipeline Progress Amidst Batoclimab Failure & Insider Selling
  • Roivant Reports Unexpected Q4 Profit, $4.3B Cash, and Breakthrough Therapy Designation for Brepocitinib
  • Roivant Posts Unexpected Q4 Profit of $355.7M Driven by $770M Moderna Settlement
  • Roivant Sciences CEO Sells $8.45 Million in Shares Near 52-Week High
  • Batoclimab Fails Phase 3 TED Studies; Roivant Expands Brepocitinib Program & Repurchases $109.7M Shares

Financial Snapshot

Fiscal year ended March 31, 2026
Revenue
$8.26M
Net Income
-$299.77M
Diluted EPS
-$0.54
Op. Cash Flow
-$750.35M
Free Cash Flow
-$758.56M
Operating Income
-$515.07M
Cash & Equivalents
$1.42B
Debt / Equity
0.00×
Net Margin
-36.29×
Shares Outstanding
720.35M sh
Source: 10-K · filed 2026-05-20 · accession 0001635088-26-000061
$38.68 +0.06% today
52-week range · as of 2026-11-09 $19.79 – $42.5
Market cap
$28.01B
Volume
4M (0.5× avg)
3-mo avg 7.6M
Live data · 2026-11-22 05:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ROIV - Filings & News (Page 2)

ROIV
May 20, 2026, 7:17 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $31.00
Real-time Price: $38.68 info
Change: +$7.68 (+25%) info
Market Cap: $28.008B info
ROIV
May 20, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $29.11
Real-time Price: $38.68 info
Change: +$9.57 (+33%) info
Market Cap: $28.008B info
ROIV
May 20, 2026, 7:08 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $28.10
Real-time Price: $38.68 info
Change: +$10.58 (+38%) info
Market Cap: $28.008B info
ROIV
Apr 20, 2026, 6:27 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $29.08
Real-time Price: $38.68 info
Change: +$9.60 (+33%) info
Market Cap: $28.008B info
ROIV
Apr 02, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $27.50
Real-time Price: $38.68 info
Change: +$11.18 (+41%) info
Market Cap: $28.008B info
ROIV
Apr 02, 2026, 5:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $27.50
Real-time Price: $38.68 info
Change: +$11.18 (+41%) info
Market Cap: $28.008B info
ROIV
Mar 04, 2026, 3:04 PM EST
Source: Wiseek News
Importance Score:
9
Price at Filing: $29.62
Real-time Price: $38.68 info
Change: +$9.07 (+31%) info
Market Cap: $28.008B info
ROIV
Mar 03, 2026, 5:11 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $28.50
Real-time Price: $38.68 info
Change: +$10.18 (+36%) info
Market Cap: $28.008B info
ROIV
Mar 03, 2026, 7:23 AM EST
Source: Wiseek News
Importance Score:
9
Price at Filing: $27.84
Real-time Price: $38.68 info
Change: +$10.84 (+39%) info
Market Cap: $28.008B info
ROIV
Mar 03, 2026, 7:13 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $27.84
Real-time Price: $38.68 info
Change: +$10.84 (+39%) info
Market Cap: $28.008B info
ROIV
Feb 19, 2026, 4:24 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $27.50
Real-time Price: $38.68 info
Change: +$11.18 (+41%) info
Market Cap: $28.008B info
ROIV
Feb 13, 2026, 9:02 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $26.92
Real-time Price: $38.68 info
Change: +$11.76 (+44%) info
Market Cap: $28.008B info
ROIV
Feb 13, 2026, 9:00 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $26.92
Real-time Price: $38.68 info
Change: +$11.76 (+44%) info
Market Cap: $28.008B info
ROIV
Feb 11, 2026, 5:53 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $26.60
Real-time Price: $38.68 info
Change: +$12.08 (+45%) info
Market Cap: $28.008B info
ROIV
Feb 09, 2026, 4:13 PM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $27.67
Real-time Price: $38.68 info
Change: +$11.01 (+40%) info
Market Cap: $28.008B info
ROIV
Feb 06, 2026, 7:31 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $23.00
Real-time Price: $38.68 info
Change: +$15.68 (+68%) info
Market Cap: $28.008B info
ROIV
Feb 06, 2026, 7:12 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $23.24
Real-time Price: $38.68 info
Change: +$15.44 (+66%) info
Market Cap: $28.008B info
ROIV
Jan 02, 2026, 8:19 AM EST
Filing Type: 144
Importance Score:
7
Price at Filing: $21.75
Real-time Price: $38.68 info
Change: +$16.93 (+78%) info
Market Cap: $28.008B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets